U.S. markets open in 8 hours 19 minutes

Corcept Therapeutics Incorporated (CORT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
26.60-0.02 (-0.08%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close26.62
Open26.68
Bid0.00 x 2900
Ask0.00 x 800
Day's Range26.50 - 27.22
52 Week Range9.70 - 31.18
Volume493,083
Avg. Volume662,556
Market Cap3.121B
Beta (5Y Monthly)N/A
PE Ratio (TTM)29.89
EPS (TTM)0.89
Earnings DateMay 03, 2021 - May 07, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est27.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-6% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results
    GlobeNewswire

    Corcept Therapeutics Announces Fourth Quarter and Full-Year 2020 Audited Financial Results

    2020 revenue of $353.9 million, compared to $306.5 million in 2019Fourth quarter revenue of $85.7 million, compared to $87.9 million in 20192020 GAAP net income of $106.0 million, compared to $94.2 million in 2019Fourth quarter GAAP net income of $26.0 million, compared to $29.4 million in fourth quarter 2019Cash and investments of $476.9 million at year-end, compared to $315.3 million at year-end 2019Acquisition of 458,769 shares pursuant to the company’s stock repurchase programReiterated 2021 revenue guidance of $375 – 405 million MENLO PARK, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter- and year-ended December 31, 2020. Corcept’s 2020 revenue was $353.9 million, compared to $306.5 million in 2019. Fourth quarter revenue was $85.7 million, compared to $87.9 million in the fourth quarter of 2019. The company reiterated its 2021 revenue guidance of $375 – 405 million. GAAP net income was $106.0 million for the year and $26.0 million in the fourth quarter of 2020, compared to $94.2 million for the year and $29.4 million in the fourth quarter of 2019. Excluding non-cash expenses related to stock-based compensation and the utilization of deferred tax assets, together with related income tax effects, non-GAAP net income was $34.7 million in the fourth quarter, compared to $40.3 million in the fourth quarter of 2019. For the full-year, non-GAAP net income was $145.6 million, compared to $133.3 million in 2019. A reconciliation of GAAP to non-GAAP net income is included below. Cash and investments increased by $32.7 million in the fourth quarter, to $476.9 million at December 31, 2020. At December 31, 2019, the balance of cash and investments was 315.3 million. The company spent $9.7 million in the fourth quarter repurchasing 458,769 shares of common stock pursuant to its stock repurchase program. Under the currently authorized terms of that program, $190.3 million remains available for the repurchase of shares. “Corcept’s financial and clinical accomplishments in 2020 lay the foundation for significant progress this year,” said Joseph K. Belanoff, MD, Corcept’s Chief Executive Officer. “As the COVID-19 pandemic is brought under control, the easing of public health restrictions and greater willingness of patients to visit their doctors will allow more physicians to diagnose and optimally treat patients with Cushing’s syndrome. We expect revenue next year of $375 – 405 million. “Improving conditions should also permit more rapid progress in our clinical development programs, many of which have been significantly slowed by the pandemic,” he added. We are currently evaluating our proprietary, selective cortisol modulators as potential treatments for patients with metastatic ovarian and pancreatic cancer, castration-resistant prostate cancer, adrenal cancer, Cushing’s syndrome, antipsychotic-induced weight gain and non-alcoholic steatohepatitis. We will have topline data from our ovarian and pancreatic cancer trials in the second quarter. In the fourth quarter, we plan to initiate a Phase 2 trial in patients with amyotrophic lateral sclerosis (ALS).” About Corcept Therapeutics Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders. GAAP Measures of Net Income To supplement our financial results presented on a GAAP basis, we use non-GAAP measures of net income, basic net income per share and diluted net income per share that exclude the following non-cash expenses – (i) stock-based compensation, (ii) our use of deferred tax assets to offset current tax expense and (iii) related income tax effects. We believe these non-GAAP measures help investors evaluate our financial performance and potential future results. Our non-GAAP measures may be different from, and not directly comparable to, those used by other companies. They are not a substitute for comparable GAAP measures and should not be considered in isolation. Investors should read our non-GAAP presentation in conjunction with our financial statements prepared in accordance with GAAP. Forward-Looking Statements Statements in this press release, other than statements of historical fact, are forward-looking statements based on our current plans and expectations that are subject to risks and uncertainties that might cause our actual results to differ materially from those statements express or imply. These risks and uncertainties include, but are not limited to, the completion of our financial closing procedures and any adjustments that may result from the completion of the annual independent audit of our consolidated financial statements; our ability to operate our business and achieve our goals and conduct our clinical trials during the COVID-19 pandemic and to generate sufficient revenue to fund our commercial operations and development programs; the availability of competing treatments, including generic versions of Korlym; our ability to obtain acceptable prices or adequate insurance coverage and reimbursement for Korlym; risks related to the development of our product candidates, including their clinical attributes, regulatory approvals, mandates and oversight, and other requirements; and the scope and protective power of our intellectual property. These and other risks are set forth in our SEC filings, which are available at our website and the SEC’s website. In this press release, forward-looking statements include those concerning our 2021 revenue guidance and our stock repurchase program; the progress, enrollment, timing, design and results of our clinical trials; the course of the COVID-19 pandemic and its impact on patients, physicians, medical practice and clinical research activities; and the clinical and commercial attributes of Korlym, relacorilant, exicorilant and miricorilant and other proprietary, selective cortisol modulators. We disclaim any intention or duty to update forward-looking statements made in this press release. CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except per share data) December 31, 2020 (1) December 31, 2019 (1) Assets Cash and investments$476,892 $315,314 Trade receivables, net of allowances26,198 19,928 Inventory21,157 17,405 Operating lease right-of-use asset2,509 3,446 Deferred tax assets, net31,603 45,677 Other assets13,372 10,542 Total assets$571,731 $412,312 Liabilities and Stockholders’ Equity Accounts payable$10,554 $7,537 Operating lease liabilities2,551 3,461 Other liabilities35,288 30,132 Stockholders' equity523,338 371,182 Total liabilities and stockholders’ equity$571,731 $412,312 (1) Derived from audited financial statements at that date CORCEPT THERAPEUTICS INCORPORATED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(In thousands, except per share data) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 2019Revenues Product revenue, net$85,735 $87,895 $353,874 $306,486 Operating expenses Cost of sales1,254 1,436 5,582 5,504 Research and development28,275 24,312 114,764 89,017 Selling, general and administrative25,696 27,131 105,326 100,359 Total operating expenses$55,225 $52,879 $225,672 $194,880 Income from operations30,510 35,016 128,202 111,606 Interest and other income297 1,444 3,400 5,070 Income before income taxes30,807 36,460 131,602 116,676 Income tax expense(4,813) (7,079) (25,591) (22,495)Net income$25,994 $29,381 $106,011 $94,181 Other comprehensive income (loss): Net unrealized gain on available-for-sale investments, net of tax impact of $96, $20, $15 and $(104), respectively(309) (62) (50) 327 Foreign currency translation loss, net of tax147 9 204 4 Total comprehensive income$25,832 $29,328 $106,165 $94,512 Basic net income per share$0.22 $0.26 $0.92 $0.82 Diluted net income per share$0.20 $0.24 $0.85 $0.77 Shares used in computing basic net income per common share116,320 114,347 115,412 114,349 Shares used in computing diluted net income per common share127,423 122,688 124,194 122,566 CORCEPT THERAPEUTICS INCORPORATED RECONCILIATION OF GAAP TO NON-GAAP NET INCOME(In thousands, except per share data) Three Months Ended Year Ended December 31, December 31, 2020 2019 2020 2019GAAP net income$25,994 $29,381 $106,011 $94,181 Non-cash expenses (benefits) Stock-based compensation Cost of sales15 39 66 144 Research and development2,865 2,707 11,222 9,541 Selling, general and administrative5,550 4,864 22,251 19,628 Total stock-based compensation8,430 7,610 33,539 29,313 Deferred income taxes2,311 5,146 14,089 16,877 Income tax effect of non-GAAP adjustments (1)(2,023) (1,826) (8,049) (7,035)Non-GAAP net income, adjusted for non-cash expenses$34,712 $40,311 $145,590 $133,336 GAAP basic net income per share$0.22 $0.26 $0.92 $0.82 GAAP diluted net income per share$0.20 $0.24 $0.85 $0.77 Non-GAAP basic net income per share, adjusted for non-cash expenses per share$0.30 $0.35 $1.26 $1.17 Non-GAAP diluted net income per share, adjusted for non-cash expenses per share$0.27 $0.33 $1.17 $1.09 Shares used in computing basic net income per common share116,320 114,347 115,412 114,349 Shares used in computing diluted net income per common share127,423 122,688 124,194 122,566 (1) Calculated by applying the statutory tax rate to the pre-tax, non-discrete, non-GAAP adjustments. CONTACT:Christopher S. James, MDDirector, Investor RelationsCorcept Therapeutics650-684-8725cjames@corcept.com www.corcept.com

  • 15 Best Small-Cap Healthcare Stocks to Buy
    Insider Monkey

    15 Best Small-Cap Healthcare Stocks to Buy

    In this article, we present the 15 Best Small-Cap Healthcare Stocks to Buy. If you’re in a hurry, click to skip ahead and see the 5 Best Small-Cap Healthcare Stocks to Buy. The term small cap can be used to define established companies with a small market capitalization ranging anywhere between $300 million and $2 […]